CP
IONS icon

Corbenic Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Corbenic Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-68
Closed -$3K – 216
2017
Q3 		$3K Buy
+68
New +$3.56K ﹤0.01% 221
2017
Q1 		– Sell
-135
Closed -$6K – 214
2016
Q4 		$6K Hold
135
– – 0.01% 151
2016
Q3 		$5K Buy
+135
New +$4.22K 0.01% 154

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Corbenic Partners's IONS Position: Q4 2017 in Review

Corbenic Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 68 shares — an estimated $3K sold.

Corbenic Partners first reported a position in IONS in Q3 2016 and held it in 3 quarters. The position peaked at $6K in Q4 2016. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

  • Corbenic Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Corbenic Partners sold 68 Ionis Pharmaceuticals shares in Q4 2017, an estimated $3K.
  • Corbenic Partners first reported a position in Ionis Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Corbenic Partners's Ionis Pharmaceuticals position peaked at $6K in Q4 2016.
  • 316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on Corbenic Partners's 13F filing for Q4 2017, filed 25 Jan 2018.